AstraZeneca PLC on Saturday said new data show its Farxiga ‘significantly’ lowers the risk of cardiovascular death in patients with heart failure.

Pooled analysis of the Dapa-HF and Deliver trials showed that Farxiga reduced the risk of cardiovascular death by 14% over the median follow-up of 22 months. It reduced total hospitalisation for heart failure by 29%.

The two trials compared Farxiga to placebo.

‘The reduction in risk of cardiovascular death was consistent across pre-specified subgroups and is the first analysis to demonstrate a mortality benefit with a HF medication in patients with HF across the left ventricular ejection fraction range,’ it said.

Copyright 2022 Alliance News Limited. All Rights Reserved.